Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Jayanta Debnath · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $713,896 — PROJECT SUMMARY Glial pathology is increasingly recognized as a key feature in neurodegenerative diseases. However, the exact mechanisms that promotes glial pathology remain unclear. Several studies implicate the autophagy machinery, a highly conserved lysosomal degradation pathway, in maintaining p…
Aaron Clifford Brown · MAINEHEALTH · 2023 · $430,000 — Project Summary/Abstract The obesity epidemic is a global public health issue, that leads to an increased risk for type 2 diabetes and cardiovascular disease. Hypertrophy, inflammation, and excess lipid accumulation in white adipocytes within fat tissue are hallmarks of obesity that contribute to me…
VALERIE B GOUON-EVANS · BOSTON MEDICAL CENTER · 2023 · $536,021 — PROJECT SUMMARY Liver transplantation is currently the only treatment for acute and chronic liver failure. Given the shortage of donor livers, hepatocyte transplantation is considered a potential treatment for liver diseases and a bridge for patients awaiting liver transplantation, but its applicati…
Amaia Lujambio · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2023 · $607,771 — Chronic liver disease and its common sequela cirrhosis, are growing public health concerns, and major risk factors for the development of hepatocellular cancer (HCC). HCC incidence and mortality is growing in the USA. Optimal medical therapies for HCC are lacking. FDA approved agents are modestly ef…
KEBIN LIU · CHARLIE NORWOOD VA MEDICAL CENTER · 2023 — Project Summary IFN was an FDA-approved agent for human cancer therapy and is currently used as exogenous recombinant protein or protein prodrugs. The use of IFN in human cancer therapy has been limited by the ineffective dosing and high toxicity. This proposal develops a lipid nanoparticle encap…
Enrico Tapavicza · CALIFORNIA STATE UNIVERSITY LONG BEACH · 2023 · $147,500 — Project Summary/Abstract There is a dire need in developing new molecular paradigms for pharmacotherapy to address problems of poor drug selectivity, causing side effects, drug resistance, and environmental toxicity. Currently, over 85 % of the drugs in clinical research are discarded due to poor se…
Kerry S Campbell · THOMAS JEFFERSON UNIVERSITY · 2023 · $502,627 — Project Summary NK cells are capable of killing virus-infected and cancer cells and, therefore, play an important role in innate host defense. Unlike cytotoxic T lymphocytes (CTL), whose cytolytic activity is induced by productive TCR engagement with cognate pMHC ligands, activation of NK cells is r…
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $387,750 — Gene editing is a promising strategy for treating or even permanently curing genetic diseases. In particular, a new technique called prime editing has the potential to make small targeted insertions, deletions, and substitutions with very high potential coverage of known disease- causing mutations, …
Yizhou Dong · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $464,750 — Project Summary Cell-specific drug delivery represents one of the most important research areas in the field of drug delivery. Particularly, there are formidable challenges for in vivo mRNA delivery. For example, therapeutic window for current delivery systems is relatively narrow. A large number o…
Vladimir R Muzykantov · UNIVERSITY OF PENNSYLVANIA · 2023 · $792,842 — Clinical approval of Lipid Nano Particles (LNP) for RNA heralded the advent of nanotechnology- based pharmacotherapy. Yet, RNA delivery to extra-hepatic sites remains a major unmet challenge. Weissman pioneered modifications of mRNA providing effective translation in diverse cell types, while Muzyka…
Bulent Ozpolat · METHODIST HOSPITAL RESEARCH INSTITUTE · 2023 · $390,063 — Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes. Several molecular targets have been identified for breast cancer treatment, but currently, there is no approved, broadly applicable targeted therapy for TNBC. Through 10 years of re…
Eric Paul Dixon · NIGHTHAWK BIOSCIENCES, INC. · 2023 · $274,649 — PROJECT SUMMARY To achieve the FDA’s required Sterility Assurance Level for use in humans, pharmaceutical products must undergo terminal sterilization or aseptic manufacturing. This can be accomplished using physical or chemical methods such as heat or formaldehyde for simple drug formulations; howe…
Virender Kumar · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2023 · $1 — PROJECT SUMMARY This K01 application aims to promote the applicant's development to become a multi-disciplinarily trained and independent academic researcher. This application's collective strengths are defined in these 3 major areas: 1) Credentials: PI's application builds upon his productive trac…
MICHAEL P CZECH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2022 · $582,900 — Abstract The overarching long term goal of our laboratory is to understand and exploit how adipose tissues exert powerful control over whole body glucose tolerance and insulin sensitivity. Small amounts of mouse brown (BAT) or human “Beige” adipocytes transplanted into recipient mice can improve glu…
Craig Lewis Duvall · VANDERBILT UNIVERSITY · 2022 · $204,011 — Project Summary / Abstract Osteoarthritis (OA) is a chronic degenerative disease that affects joints and their surrounding tissues. OA can occur spontaneously with aging or be secondary to injury in the case of post-traumatic osteoarthritis (PTOA). OA/PTOA causes significant morbidity and loss of qu…
Amaia Lujambio · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2022 · $607,766 — Chronic liver disease and its common sequela cirrhosis, are growing public health concerns, and major risk factors for the development of hepatocellular cancer (HCC). HCC incidence and mortality is growing in the USA. Optimal medical therapies for HCC are lacking. FDA approved agents are modestly ef…
Conrrad Makea Rupe Nicholls · PURDUE UNIVERSITY · 2022 · $37,658 — Project Summary/Abstract Flaviviruses (a family of over 90 known viruses, including Zika, dengue and West Nile) are significant human pathogens affecting 3.1 billion people annually, and most of these enveloped viruses do not have any viable vaccines or antivirals capable of combating their spread.…
Johannes Morstein · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 · $85,960 — Project Summary Significant progress in human cancer therapy in the last decade has been driven by conceptionally new approaches to targeting cancer, including cancer immunotherapy, cancer nanotherapy, or new types of biologics and small molecules. Both my dissertation and postdoc research will be f…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2022 · $391,721 — Project Summary The programmable CRISPR/Cas gene editing system has great potential for cancer treatment due to the ability to precisely inactivate or repair cancer-related genes. However, delivery of CRISPR to solid tumors for efficient cancer therapy remains limited by the uniquely stiff and fibro…
JANICE CHOU · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2022 · $1,602,501 — The rAAV-co-G6PC vector used in the current phase I/II clinical trial is episomally expressed and the long-term durability of expression in humans is currently being established. We therefore sought to explore the use of the CRISPR/Cas9 technology to correct a pathogenic GSD-Ia variant in its native…